EUVIMEDEUVIMED entdecken
Crossref

Managementul efectelor COVID-19 asupra simptomelor tractului urinar inferior la pacientii cu hiperplazie benigna de prostata

R.T. VRABIE, A.G. VRABIE, M. C. DUGANOPAIȚ, I. A. BĂDĂRĂU, I. R. PAPACOCEA

Management in Health · 2023

DOI: 10.5233/1nf2bz33 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Management in Health, 2023. Verfasst von R.T. VRABIE und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION. The novel sever acute respiratory syndrome coronavirus2 (SARS-CoV-2) was initial discovered in Wuhan, China in 2019, and since 2020it had a major impact on medical practice. Since its discovery it has spreadthroughout the entire world and the coronavirus disease (COVID-19) wasdeclared a pandemic by the World Health Organization (WHO). At the beginningit was believed that is only a pneumonia with flu like symptoms, but as new casesemerged other symptoms appeared among COVID-19 patients affectingcardiovascular system, gastrointestinal tract and kidney. The interaction betweenACE receptors and virus was supposed to be the cause of the various symptoms.OBJECTIVES. The aim of the study was to see the effect of SARS-CoV-2infection on patients with benign prostate hyperplasia (BPH), between acuteinfection and after 1 month regarding urological symptoms and to find predictorsfor urine retention in such patients.MATERIALS AND METHODS. We evaluated all male patients admitted inour hospital with SARS-CoV-2 infection who expressed different forms of COVID-19. We enrolled patients who were previously diagnosed with BPH. We gatheredinformation of their condition prior to infection as prostate volume, postvoidingresidual urine, International Prostate Symptom Score (IPSS) and othercomorbidities. All enrolled patients were assessed using clinical examinationdigital rectum examination (DRE), pelvi-abdominal ultrasonography for prostatevolume and postvoiding residual urine (PVR) and IPSS for lower urinary tractsymptoms. We performed a multivariate analysis to detect the correlation betweenurinary symptoms and scores and COVID-19 disease.RESULTS. Thirty-tree patients, who were prior diagnosed with BPH, wereenrolled. The mean age (±SD) was 71.85 ± 9.12. In the pre and post COVID-19group, the mean IPSS was 11.76 ± 5.28 and 18.97 ± 7.99 (P

Zitieren

APA

VRABIE, R., VRABIE, A., DUGANOPAIȚ, M. C., BĂDĂRĂU, I. A., & PAPACOCEA, I. R. (2023). Managementul efectelor COVID-19 asupra simptomelor tractului urinar inferior la pacientii cu hiperplazie benigna de prostata. Management in Health. https://doi.org/10.5233/1nf2bz33

Vancouver

VRABIE R, VRABIE A, DUGANOPAIȚ MC, BĂDĂRĂU IA, PAPACOCEA IR. Managementul efectelor COVID-19 asupra simptomelor tractului urinar inferior la pacientii cu hiperplazie benigna de prostata. Management in Health. 2023. doi:10.5233/1nf2bz33

BibTeX
@article{VRABIE2023,
  author = {VRABIE, R.T. and VRABIE, A.G. and DUGANOPAIȚ, M. C. and BĂDĂRĂU, I. A. and PAPACOCEA, I. R.},
  title = {Managementul efectelor COVID-19 asupra simptomelor tractului urinar inferior la pacientii cu hiperplazie benigna de prostata},
  journal = {Management in Health},
  year = {2023},
  doi = {10.5233/1nf2bz33}
}
Kostenlos starten →